Voloridge Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Voloridge Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-311,358	Closed	-$31.7M	–	1663
2023 Q2	$31.7M	Buy	311,358 +151,542	+95%	+$14.3M	0.15%	191
2023 Q1	$14.5M	Sell	159,816 -58,031	-27%	-$3.41M	0.07%	358
2022 Q4	$8.28M	Sell	217,847 -101,933	-32%	-$3.51M	0.05%	486
2022 Q3	$8.04M	Buy	319,780 +100,927	+46%	+$2.8M	0.04%	515
2022 Q2	$6.65M	Sell	218,853 -35,452	-14%	-$1.06M	0.03%	571
2022 Q1	$8.33M	Sell	254,305 -68,281	-21%	-$2.03M	0.05%	467
2021 Q4	$8.51M	Buy	+322,586	New	+$25M	0.05%	517
2021 Q3	–	Sell	-70,990	Closed	-$10M	–	1938
2021 Q2	$10M	Buy	70,990 +54,301	+325%	+$6.13M	0.07%	410
2021 Q1	$1.66M	Buy	+16,689	New	+$1.95M	0.01%	874
2020 Q2	–	Sell	-2,880	Closed	-$416K	–	1573
2020 Q1	$416K	Sell	2,880 -11,652	-80%	-$2.25M	0.01%	768
2019 Q4	$2.97M	Buy	+14,532	New	+$2.65M	0.06%	397
2019 Q2	–	Sell	-5,272	Closed	-$451K	–	1168
2019 Q1	$451K	Buy	+5,272	New	+$438K	0.01%	693

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Voloridge Investment Management's RETA Position: Q3 2023 in Review

Voloridge Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 311,358 shares — an estimated $31.7M sold.

Voloridge Investment Management first reported a position in RETA in Q1 2019 and held it in 12 quarters. The position peaked at $31.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Voloridge Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Voloridge Investment Management sold 311,358 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $31.7M.
Voloridge Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 12 quarters.
Voloridge Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $31.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Voloridge Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.